As policy agendas for 2015 come into sharper focus, much of the national conversation is aimed at tackling challenges in biomedical innovation. The first two months of the year alone have seen landmark proposals from Congress and the Obama Administration, including the House’s 21st Century Cures initiative, a bipartisan Senate working group focused on medical progress, President Obama’s Precision Medicine Initiative and a number of additional priorities being advanced by federal agencies and other stakeholders.
On March 13, the Engelberg Center for Health Care Reform hosted the State of Biomedical Innovation Conference to provide an overview of emerging policy efforts and priorities related to improving the biomedical innovation process. Senior leaders from government, academia, industry, and patient advocacy shared their thoughts on the challenges facing medical product development and promising approaches to overcome them. The discussion also examined the data and analyses that provide the basis for new policies and track their ultimate success.
Join the conversation by following @BrookingsMed or #biomed
State of biomedical innovation conference
State of biomedical innovation conference: Panel 2
Agenda
-
March 13
-
Emerging Issues and Policy Priorities in 2015
9:20 am - 10:30 am
Jeff Allen Executive Director - Friends of Cancer ResearchBill Chin Executive Vice President, Science and Regulatory Advocacy - Pharmaceutical Research and Manufacturers of America (PhRMA)Pamela McInnes Deputy Director, National Center for Advancing Translational Sciences - National Institutes of HealthPamela Tenaerts Executive Director - Clinical Trials Transformation Initiative -
Tracking Innovation and Measuring Policy Success
10:30 am - 11:30 am
Murray Aitken Senior Vice President - IMS HealthJonathan Leff Partner - Deerfield ManagementPeter Neumann Professor of Medicine, Sackler School of Graduate Biomedical Sciences - Tufts University
-